Literature DB >> 7692199

Pulmonary toxicity of ABVD chemotherapy and G-CSF in Hodgkin's disease: possible synergy.

J H Matthews.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7692199     DOI: 10.1016/0140-6736(93)92033-p

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  10 in total

Review 1.  Clinical toxicity of cytokines used as haemopoietic growth factors.

Authors:  T Vial; J Descotes
Journal:  Drug Saf       Date:  1995-12       Impact factor: 5.606

Review 2.  Recombinant methionyl granulocyte colony-stimulating factor (filgrastim): a new dimension in immunotherapy.

Authors:  G Schwab; T Hecht
Journal:  Ann Hematol       Date:  1994-07       Impact factor: 3.673

Review 3.  Growth factors and hematopoietic recovery.

Authors:  S C Gulati; R Gopal; J B Prowda; S Spanik; M Jain; A Gopal
Journal:  Med Oncol       Date:  1994       Impact factor: 3.064

4.  Meta-Analysis of Risk Factors and Incidence of Interstitial Pneumonia With CHOP-Like Regimens for Non-Hodgkin Lymphoma.

Authors:  Jing Yang; Limin Chai; Junting Jia; Liping Su; Zhiying Hao
Journal:  Front Oncol       Date:  2022-06-01       Impact factor: 5.738

5.  Interstitial pneumonia in patients receiving granulocyte colony-stimulating factor during chemotherapy: survey in Japan 1991-96.

Authors:  N Niitsu; S Iki; K Muroi; S Motomura; M Murakami; H Takeyama; A Ohsaka; A Urabe
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  Interstitial pneumonia following administration of pegfilgrastim during carboplatin and etoposide chemotherapy for small-cell lung cancer.

Authors:  Masayuki Shirasawa; Yoshiro Nakahara; Hideyuki Niwa; Shinya Harada; Takahiro Ozawa; Seiichiro Kusuhara; Masashi Kasajima; Yasuhiro Hiyoshi; Jiichiro Sasaki; Noriyuki Masuda
Journal:  Mol Clin Oncol       Date:  2016-10-26

7.  Pulmonary toxicity after granulocyte colony-stimulating factor-combined chemotherapy for non-Hodgkin's lymphoma.

Authors:  N Yokose; K Ogata; H Tamura; E An; K Nakamura; K Kamikubo; S Kudoh; K Dan; T Nomura
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

8.  Serious pulmonary complications in patients receiving recombinant granulocyte colony-stimulating factor during BACOP chemotherapy for aggressive non-Hodgkin's lymphoma.

Authors:  K I Lei; W T Leung; P J Johnson
Journal:  Br J Cancer       Date:  1994-11       Impact factor: 7.640

9.  Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours.

Authors:  A B Simpson; J Paul; J Graham; S B Kaye
Journal:  Br J Cancer       Date:  1998-10       Impact factor: 7.640

10.  A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity.

Authors:  A Gibb; A Greystoke; M Ranson; K Linton; S Neeson; G Hampson; T Illidge; E Smith; C Dive; A Pettitt; A Lister; P Johnson; J Radford
Journal:  Br J Cancer       Date:  2013-10-17       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.